NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn’s disease

T Watanabe, A Kitani, W Strober

NOD2 signalling can both positively and negatively regulate Toll-like receptor (TLR) responses. Previous studies have shown that lack of NOD2 signalling (in NOD2 knockout mice) leads to increased peptidoglycan induction of interleukin (IL)-12 via TLR2. Studies in this issue of Gut show that lack of NOD2 signalling (in patients with NOD2 mutations) leads to decreased CpG induction of tumour necrosis factor and IL-8 via TLR9. The first type of abnormality suggests that NOD2 mutations act by enhancing effector T cell function and the second that NOD2 mutations act by impairing regulatory T cell function. We weigh these possibilities.

Several years ago it was discovered that homozygous (or compound heterozygous) mutations of CARD15, a gene encoding NOD2 (nucleotide oligomerisation domain 2), are a major susceptibility factor underlying a significant subgroup of patients with Crohn’s disease in Western countries.1-4 More recently it has been shown that mutations of this gene are also associated with diseases that are immunologically related to Crohn’s disease, such as early onset sarcoidosis.5 Thus it has become increasingly clear that these mutations offer an extraordinary window on the function of the mucosal immune system and how defects in such function lead to disease.

The road to understanding the consequences of NOD2 mutations begins with knowledge of how NOD2 functions in normal individuals. NOD2 is now known to be a member of a large and somewhat heterogeneous protein family known as the NOD-LRR (leucine-rich repeat) protein family that are grouped together because they more or less share the same structural regions: an LRR domain, a NOD domain, and a CARD (caspase recruitment domain) (as in the case of NOD2) or PYRIN domain.6 The LRR domain is a cognate of a similar domain, a NOD-LRR family member that, on binding of a ligand to the LRR, facilitates a conformational change in the molecule and thus its activation. This conformational change also involves the third region of the molecule, the CARD or PYRIN domains, in that it facilitates the interaction of these effector domains with a “downstream” protein capable of initiating an inflammatory programme.7 It should be noted however that the CARD and PYRIN domains interact with different downstream molecules and thus lead to different types of inflammatory responses; thus, while activation of the CARD domain results in activation of nuclear factor kappa B (NFκB), activation of the PYRIN domain leads to activation of pro-caspase 1 and, ultimately, interleukin (IL)-1β.8 9 Two other points concerning NOD-LRR proteins are firstly that they are intracellular (cytoplasmic) proteins and thus differ from TLRs that are either on the surface of cells or in phagolysosomal compartments, and secondly, while the signalling cascades of TLRs and NODs differ very considerably, points of intersection do occur; this introduces the possibility that NOD-LRR family members regulate TLR responses. As we shall see, this is important in the case of NOD2.

A major step forward in the understanding of NOD2 and the structurally similar NOD-LRR family member, NOD1, was the discovery that these molecules bind (via their LRR domains) specific microbial peptides derived from peptidoglycan (PGN), a glycoprotein found in the wall of virtually all bacteria, including those comprising the commensal microbial microflora of the gut. These consist of muramyl dipeptide (MDP) in the case of NOD2 and γ-D-glutamyl meso diaminopimelic acid in the case of NOD1.10 11 As PGN is also a ligand for TLR2,12 this finding implies that PGN signals the cell in three ways: at the cell surface as an intact molecule interacting with TLR2 and in the cell cytoplasm as a peptide breakdown product interacting with NOD2 or NOD1. Recently, it has been shown that MDP is also recognised by cryopyrin,13 another NOD-LRR family member that is similar to NOD2 and NOD1, except that it has a PYRIN region instead of a CARD region; this brings to four the number of ways PGN can signal the cell. Interestingly, as in the case of NOD2, mutations in cryopyrin are also associated with inflammatory diseases.14 Finally, studies of the cellular distribution of NOD2 show that it is expressed in antigen presenting cells (APCs) and in a subset of epithelial cells at the base of the intestinal crypts, known as Paneth cells.15 Thus it is apparent that NOD2 is well positioned to influence responses to both commensal and pathogenic organisms in the gut. NOD1, on the other hand, is expressed in all columnar epithelial cells and in APCs.

MDP induced NOD2 signalling results in NFκB activation and subsequent NFκB dependent cytokine responses. However, these are much weaker than those elicited by PGN induced TLR2 signalling and may thus be a relatively unimportant aspect of NOD2 function.16 17 This is in fact supported by recent studies that show that NOD2 exerts strong regulatory influence on TLR signalling, both positive and negative. An important example of negative regulation that relates to the possible role of NOD2 mutations in Crohn’s disease has emerged from studies of NOD2 effects on PGN induced IL-12 and IL-18 production, two cytokines whose synthesis is dependent on activation of NFκB.18 19 These studies have provided evidence that MDP activation of NOD2 induces only low levels of IL-12 (p70 heterodimer) synthesis and, perhaps more importantly, markedly inhibits the capacity of PGN to induce this cytokine.20 This negative effect of NOD2 signalling is brought into bold relief by study of cells from NOD2 knockout mice that lack NOD2: such cells produce markedly increased amounts of IL-12. The molecular mechanism of this NOD2 regulatory
effect appears to involve subtle but important differences in activation of NFKB by PGN in the presence and absence of NOD2 signalling. In the presence of NOD2, PGN signalling results in relatively low amounts of c-Rel translocation to the nucleus, a key event in induction of IL-12 by NFKB. In contrast, in the absence of NOD2, PGN signalling results in relatively high amount of c-Rel translocation and thus greatly amounts of IL-12 synthesis.

As IL-12 is one of the main initiators of the Th1 inflammatory response and higher amounts of IL-12 production are reflected in higher interferon γ (IFN-γ) production, this regulatory effect of NOD2 on PGN responses could be the basis of the fact that NOD2 mutations (and accompanying deficiency in NOD2 function) is a susceptibility factor in Crohn’s disease. One could postulate here that the “immunostat” for innate immune responses relating to PGN derived from commensal organisms in the gastrointestinal tract is set to a lower level by the NOD2 mutations so that the mucosal environment in patients with NOD2 mutations produce a higher basal level of IL-12 and thus support Th1 responses by any number of antigens derived from ordinarily non-pathogenic organisms in the intestinal microflora. However, while this thesis is compelling in the context of animal models of mucosal inflammation and in mice that are NOD2 deficient, it has yet to be verified in humans. A second type of regulation of TLR responses exerted by NOD2 signalling is the obverse of that just discussed and involves enhancement of TLR responses. Thus evidence is also at hand showing that NOD2 signalling in human monocytytic cell lines has an enhancing effect on IL-8 and tumour necrosis factor (TNF) production induced in these cells by TLR2, TLR4, and TLR9 ligands. In addition, as discussed below, NOD2 signalling also has an enhancing effect on TLR9 responses in fresh peripheral blood human cells. These studies indicate that NOD2 modulation of TLR responses can be either positive or negative depending on the types of TLR stimuli.

What molecular mechanisms account for these very different forms of NOD2 regulation? The answer is not yet known but there is some evidence that it involves the way NOD2 and TLRs interact with RICK (RIP2), an adaptor molecule containing a CARD region that links NOD2 and TLR signalling to NFKB activation. As mentioned above, activation of NOD2 by ligand (MDP) binding to its LRR results in a change in conformation of its CARD region. This in turn leads to binding and activation of RICK via a CARD/CARD interaction. Activated RICK then ubiquitinylates the IKKγ subunit of the NFKB IKK complex and thus activates IKKβ and downstream NFkB components.

Interestingly, PGN signalling via TLR2 also leads to activation of RICK by an independent route involving MyD88 (as discussed below) so that the NOD2 and TLR2 signalling pathways intersect at RICK. 

This opens the door to the possibility that NOD2 signalling negatively regulates TLR2 signalling with respect to induction of IL-12 by imposing a form of ubiquitinylination on the IKKγ subunit of NFKB (different from that induced by TLR2) that leads to decreased c-Rel activation, as discussed above. Within this framework we can also explain enhancement of TLR responses by NOD2 signalling if we assume that some TLR responses, such as the TLR9 response to CpG stimulation, leads to activation of NFKB through activation of a canonical TLR pathway that goes through MyD88, IRAK, and TRAF6 and does not involve RICK, as indicated by the fact that RICK deficient macrophages show normal cytokine responses following CpG stimulation. In addition, even alternative TLR signalling response that moves from MyD88 directly to RICK may not lead to downregulation of cytokine responses except in the case of IL-12 which is uniquely sensitive to c-Rel activation. On the contrary, here one may see enhancement of TLR responses due to the fact that NOD2 activation upregulates MyD88 expression.

In this issue of the Gut, van Heel and colleagues report that in conformity with previous studies mentioned above, whereas MDP stimulation of peripheral blood mononuclear cells (PBMCs) from normal individuals results in 2-3-fold enhancement of CpG DNA stimulation of PBMC production of TNF-α and IL-8, such enhancement is not seen in PBMCs from patients with Crohn’s disease bearing NOD2 mutations (see page 1553). Concomitant studies of IL-12 secretion were not reported in this study or in a previous study of normal individuals and Crohn’s disease patients with NOD2 mutations, perhaps because secretion of IL-12 by PBMCs is low and thus difficult to assess. Thus we do not know if the loss of the enhancing effect of NOD2 is counterbalanced by loss of an inhibitory effect. We also do not know if the same or similar findings would be obtained if the authors had studied intestinal cells that differ considerably from peripheral cells in response to various stimuli. In any case, based on these findings, van Heel and colleagues propose that synergistic cytokine response between TLR9 and NOD2 might be beneficial in maintaining intestinal homeostasis and the lack of such synergism is a cause of Crohn’s disease.

Intestinal or mucosal homeostasis by any definition is the end result of effector cell responses that protect the individual from infections of the mucosa by pathogens and regulatory responses that protect the individual from excessive responses induced either by pathogens or by commensal organisms in the microflora. It is doubtful that disruption of mucosal homeostasis by affecting the effector cell part of the equation is the cause of Crohn’s disease as the latter is well known to be associated with an excessive Th1 immune response, especially one involving TNF-α or IL-12, both cytokines targeted for reduction in the treatment of patients with anti-TNF-α or anti-IL-12 antibodies. Nevertheless, this possibility is worth considering in view of recent information concerning the relation of NOD2 signalling in Paneth cells to the production of α-defensins.

Paneth cells are specialised epithelial cells at the base of the intestinal crypts that are characterised by dense granules containing α-defensins, peptides with bactericidal properties. As such, they fulfil an important host defence function in the gut, as shown by the fact that transgenic mice that express human α-defensin 5 are resistant to Salmonella typhimurium infection and, conversely, mice lacking the ability to process α-defensins into a mature active form are more susceptible to such infection. Of interest to the present discussion, Paneth cells express TLR9 and, as mentioned earlier, they also express NOD2. In addition, they can be triggered by CpGs and by MDP to secrete α-defensins. Thus it is reasonable to propose that the presence of NOD2 mutations renders epithelial cells unable to produce maximal amounts of α-defensins and, as a result, organisms colonise the intestinal surface that induce the inflammation in Crohn’s disease. Consistent with this notion, there is some as yet incomplete evidence that patients with Crohn’s disease, particularly those with NOD2 mutations, express decreased amounts of α-defensin 5 in the small intestinal mucosa and one line of mice lacking NOD2 exhibit reduced α-defensin mRNA expression in Paneth cells and are more susceptible to oral (but not intravenous) L monocytogenes infection of the liver. It should be noted however that these data supportive of the concept that NOD2 mutations produce a kind of immunodeficiency state that predisposes to a type of bacterial colonisation
of the gut are counterbalanced by other data that rule against this concept. Perhaps the most persuasive is that mice that lack MMP-7 (matrilysin) and that thus cannot convert α-defensin precursors into mature and active forms of α-defensins or, indeed, mice that lack Paneth cells altogether, do not spontaneously develop chronic inflammation indicates of a Crohn’s-disease-like condition, at least under the pathogen-free conditions that are able to support other causes of chronic mucosal inflammation. In addition, convincing data have yet to emerge that the intestinal surface of patients with Crohn’s disease or in spontaneous experimental models of Crohn’s disease is colonised with organisms that cause Crohn’s disease; on the contrary, there is good evidence that commensal organisms have ready access to the internal milieu of the gut, despite the presence of an intact α-defensin system, and thus have the potential to induce Crohn’s disease in patients with normal defensin production.

We come then to the second way in which intestinal homeostasis could be disturbed by lack of enhancement of TLR9 responses to CpG by NOD2 responses to MDP—namely, by the failure of the mucosal immune system in this situation to mount adequate regulatory cell (that is, tolerogenic) responses. The basis of this possibility comes from the recent observation that various forms of experimental colitis in mice are paradoxically prevented by provision of CpGs either in the form of immunostimulatory oligonucleotides or as components of so-called probiotic organisms. Furthermore, this protective effect can be traced to TLR9 stimulation, as it is not seen in mice lacking TLR9 by gene targeting or in mice deficient in the signalling of type I IFN, the cytokine class thought to be produced by plasmacytoid dendritic cells implicated in the induction of regulatory T cells. Thus these data suggest that impairment in optimal responses to CpGs via TLR9, such as that caused by lack of enhancement by NOD2 signalling, could lead to deficient regulatory T cell development and the development of Crohn’s disease due to failure to maintain tolerance to commensal organisms.

This is an interesting possibility but one that is far from being proven. Firstly, while there is ample evidence that experimental colitis can be due to deficient regulatory cell responses, there are few data that this is the case in human Crohn’s disease. Secondly, while van Heel and colleagues have shown that NOD2 signalling enhances TLR9 signalling, there is no evidence that TLR9 signalling by itself can induce regulatory T cells. Finally, and perhaps most importantly, there is a large body of evidence that under most circumstances TLR9 signalling induces Th1 responses (that is, the very type of cytokine response that underlies Crohn’s disease). This may explain the fact that delivery of CpG to mice with already established inflammation leads to intensified inflammation. The fact is that we still do not know enough about TLR9 signalling and its relation to induction of effector versus regulatory T cells to predict whether enhancement of TLR9 responses would exacerbate or abate Crohn’s disease.

The above discussion shows very clearly that we have gained a great deal of knowledge concerning the role of NOD2 in normal individuals in the past several years. Nevertheless, much remains to be learned concerning its role in disease. We believe that ultimately NOD2 mutations will prove to be the cause of Crohn’s disease, primarily because they lead to loss of negative regulatory effects on TLR signalling. However, additional studies in patients with mutations such as the one reported in this issue of Gut will be necessary to elucidate the issue.


Authors’ affiliations
T Watanabe, A Kitani, W Strober, Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Correspondence to: Dr W Strober, Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room SW3940, 10 Center Drive, Bethesda, MD 20892, USA; wstrober@niaid.nih.gov

Conflict of interest: None declared.

REFERENCES

www.gutjnl.com On October 6, 2023 by guest. Protected by copyright.
Hepatitis C

Following the TRAIL from hepatitis C virus and alcohol to fatty liver
S C Afford, D H Adams

Tumour necrosis factor related apoptosis inducing ligand or TRAIL, is a novel mediator of fatty liver disease which may provide a mechanism to explain the development of steatosis in hepatitis C virus infection and in response to alcohol

Fatty liver or steatosis is a common finding in several liver diseases, most notably non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) but is also seen more frequently in chronic hepatitis C virus (HCV) related liver disease than would be predicted by simple concurrence of the two diseases.1 Several mechanisms have been proposed to explain why steatosis might develop in chronic viral infection, including direct effects of the virus on lipid metabolism, but none of these is entirely convincing. Furthermore, steatosis is not a benign lesion but one that contributes to the progression of fibrosis, not only in NAFLD and ALD but also in HCV, in part by increasing the sensitivity of the liver to oxidative stress and cytokine mediated injury.2 The paper by Mundt and colleagues3 in this issue of Gut provides novel mechanistic insights into why steatosis develops in HCV and how it might accentuate liver injury (see page 1590). They have concentrated their efforts on a member of the tumour necrosis factor (TNF) superfamily called TRAIL or TNF related apoptosis inducing ligand. TRAIL is known to induce apoptosis in transformed cells and this group have previously shown TRAIL acting through one of its receptors called TRAIL-DR5 or TRAIL-2, mediates hepatocyte apoptosis in viral hepatitis. What they now show is that this receptor-ligand pair can also mediate hepatic steatosis in both viral hepatitis and in response to alcohol.

The authors start with the observation that expression of TRAIL is increased in the livers of patients with HCV associated steatosis and they then proceed to investigate the functional relevance of these observations in animal models. They used adenoviral gene transfer to express TRAIL in mouse liver and found that overexpression of TRAIL itself had no effect in the healthy liver. However, if gene transfer of TRAIL was preceded by high dose adenoviral infection, this sensitised the liver to respond to TRAIL expression with steatosis and hepatocyte apoptosis. Furthermore, by looking at expression of TRAIL receptors in the infected livers, the authors were able to show that viral infection downregulated a TRAIL decay receptor while increasing expression of the death domain associated TRAIL receptor TRAIL-R2, thereby providing a mechanism to explain how viral infection can amplify the effects of TRAIL. Furthermore, induction of steatosis was specific for TRAIL because overexpression of another TNFSF member Fas-L was associated with apoptosis but not steatosis.

Because nuclear factor κB (NFκB) activity is critical in determining the outcome of activation of many TNF receptors, the authors then investigated the effects of inhibiting NFκB and found that the loss of NFκB activation markedly sensitised hepatocytes to TRAIL mediated apoptosis and also resulted in the accumulation of larger amounts of fat in hepatocytes. Finally, because TNF-α plays an important role in alcoholic fatty liver disease, they investigated whether alcohol could sensitise mice to the effects of TRAIL. Intriguingly, feeding mice with 20% ethanol for four days did not lead to changes in TRAIL receptors but did sensitise animals to subsequent exposure to TRAIL but in contrast with virus infection ethanol led only to steatosis in response to TRAIL whereas TNF-α has been shown to mediate steatosis via effects on insulin resistance which can be inhibited by treatment with metformin leading the authors to investigate metformin treatment in their model. However, metformin had no protective effect on TRAIL mediated steatosis, suggesting that TRAIL induced steatosis is a direct consequence of TRAIL-R2 activation.

These observations are of major significance because they show that TRAIL is a novel mediator of fatty liver disease which may provide a mechanism to explain the development of steatosis in HCV infection. Furthermore, the fact that TRAIL expression is harmless in healthy livers whereas in the presence of viral infection it mediates hepatocyte apoptosis and steatosis and after alcohol mediates steatosis without apoptosis suggests that the outcome of TRAIL-2
active inflammation, making interpre-
some constitutively and some at sites of
ligand pairs are expressed in the liver,
ease.

viral, and/or alcohol related liver dis-

Thus the authors suggest that all trials
including hepatocellular carcinoma. 4–6
the treatment of malignant disease,

of this family of molecules in

mediated by other TNF family members.
These data provide an exciting new
insight into the pathogenesis of steato-

superfamily.7 Several of these receptor
members of the TNF receptor (TNFR)
to one or more of the 27 identified
ligands capable of binding
further because several of the TNF
ligands bind to more than one TNFR
in TNFR2, CD40, and CD30, that
can activate both cas-
pases and NFκB (fig 1). The other two
membrane receptors, TRAIL-R3 (Dcr1) and
TRAIL-R4 (Dcr2), have truncated
death domains and are not capable of
activating the caspase cascade. This led
to the assumption that they act as decoy
receptors but they may activate NFκB and
block apoptosis10 and it is possible,
given the precedent with other TNFRs
including TNFR2, CD40, and CD30, that
they might promote apoptosis via auto-
crine or paracrine activation of other
TNFR1 and Fas.11

The true biological function of TRAIL
has been difficult to define but current
evidence suggests that its main function
is as a regulator of the innate immune
response during immune surveillance
against tumours and virus infected
cells.15–18 The study by Mundt and
colleagues5 provides further evidence
that TRAIL is a critical determinant of
outcome and tissue damage in inflam-

Investigation of this molecular super-
family has come a long way since the
initial reports of the immunomodula-
tory functions of TNF-α, Fas/FasL, and
type 1 interferons.16 A major differ-
ence between TRAIL and CD95L or TNF-
α is its ability to induce apoptosis of cell
lines and tumour cells while displaying
minimal toxicity on normal cells.17 This
led to interest in TRAIL as a therapy for
cancer and subsequent clinical trials
with soluble TRAIL.18 There are cur-
rently four known membrane receptors
for TRAIL and one dimeric soluble
secreted receptor, osteoprotegerin.16

TRAIL-R1 and TRAIL-R2 are classical
TNF receptors and contain a cytoplasmic
death domain (which is also present in
other family members, including TNFR1
and Fas) and can activate both cas-
pases and NFκB as a soluble molecule.14 15

TNF was originally identified
by virtue of its sequence homology to
Fas ligand, is a type II transmembrane
protein with 281–291 amino acids and
an extracellular region which is cleaved
as a soluble molecule.14 15 TRAIL is
upregulated on the membrane of acti-

TNK receptors and contain a cytoplasmic
death domain (which is also present in
other family members, including TNFR1
and Fas) and can activate both cas-
pases and NFκB, providing a mechanism by which it could antagonise the proapoptotic effects of TRAIL-R2 activation
(adapted from Kimberley and Screaton16 and MacFarlane17).

Figure 1 Tumour necrosis factor related apoptosis inducing ligand (TRAIL) receptor signalling. Schematic

manner.10 In general, expression of the
ligands tends to be more restricted,
which makes them a more attractive
proposition to target therapeutically.
However, under certain conditions, liver
epithelial cells (hepatocytes and cholan-
giocytes) express both receptors and
ligands allowing autocrine and para-
crine interactions to regulate cellular
responses.8 The situation is complicated
further because several of the TNF
ligands bind to more than one TNFR
and moreover activation via one recep-
tor can influence activation of
another.10 An example of the latter
mechanism is the ability of activation
through CD40 on hepatocytes to induce
increased expression of Fas and secre-
tion of Fas ligand resulting in autocrine
activation of the Fas pathway.11 Similar
cooperative interactions have been
described for other receptors, including
TNFR2 and TNFR1.12 Because several of
these receptors mediate the same effects
(for example, induction of apoptosis) it
must be presumed that a considerable
degree of redundancy operates within
this family of molecules.

Investigation of this molecular super-
family has come a long way since the
initial reports of the immunomodula-
tory functions of TNF-α, Fas/FasL, and
CD40/CD154.16 It is now apparent that
TNFSF members influence a wide range
of biological functions in many cell
types. In the liver, they are involved in
modulating cell survival and apoptosis,
current study is the ability of TRAIL acting through TRAIL-R2 to induce steatosis as well as apoptosis. The authors show that the outcome of TRAIL-R2 activation is determined by the presence or absence of viral infection or toxic agents such as alcohol. Elucidating the mechanisms behind these effects will be important for understanding why particular disease triggers are associated with specific patterns of liver injury. The viral effect may be a consequence of the release of type 1 and type 2 interferons which can induce TRAIL expression on immune effector cells and prime cells for TNF mediated steatosis.

Furthermore, transfection of Hep G2 cells with the HBV encoded X antigen increases their sensitivity to TRAIL mediated apoptosis, suggesting that some viral protein may have direct effects on this pathway. The mechanisms by which ethanol and steatosis mediated by TRAIL are accentuated if NFκB is inactivated, suggesting that NFκB plays a protective role. Thus some of increased sensitivity to the effects of TRAIL in inflammatory liver disease may be a consequence of alterations in NFκB activation, possibly as a result of signals provided by other TNF family members.

It is not clear whether TRAIL in these models is presented as a membranous ligand by haematopoietic cells, as an autocrine/paracrine signal on hepatocytes, or as a soluble cytokine. Previous work in murine models of liver inflammation suggests that TRAIL expression on mononuclear cells is sufficient to drive liver damage but in models of adenoviral infection lymphocyte TRAIL is not necessary, suggesting a paracrine/autocrine mechanism involving hepatocyte TRAIL. In addition, TRAIL may be operating through other liver cell types. Apoptosis of stellate cells is an important component of the resolution phase of hepatic fibrosis and activated stellate cells show increased expression of TRAIL-R2 and increased sensitivity to apoptosis by TRAIL. The function of soluble TRAIL may prove to be important for the future of clinical trials with TRAIL. So far hepatotoxicity does not appear to have been a major side effect of TRAIL therapy but clearly from the study of Mundt and colleagues the chances of toxicity will be greater in patients with concomitant liver disease, many of whom will be screened out of phase 1/11 clinical trials and treated. Animal studies suggest that soluble TRAIL administered in vivo is much less likely to induce liver injury compared with membrane bound TRAIL. This may be because soluble TRAIL cannot engage death receptors as efficiently as membrane TRAIL or even because the soluble form inhibits activity of membrane TRAIL, as has been shown for soluble and membrane bound Fas-L.

Mundt and colleagues conclude that TRAIL may be a new therapeutic target for inhibition of hepatic steatosis. However, before this can become a reality, more needs to be known about the complex regulation and interplay of the different TNF family members in the context of liver inflammation. A further caveat also arises from the important differences between the murine and human TRAIL systems. Mice only express one death receptor, which is structurally related to human TRAIL-R2, and the mouse homologues of human TRAIL-R3 and TRAIL-R4 show distinct, opposing roles during liver injury and repair.

Conflict of interest: None declared.

Correspondence to: Professor D Adams, Liver Research Laboratories and MRC Centre for Immune Regulation, Institute for Biomedical Research, Queen Elizabeth Hospital, University of Birmingham, Birmingham, UK

Conflict of interest: None declared.

REFERENCES


Predicting survival in hepatitis B

M Sherman

Alanine aminotransferase (ALT) level alone is not an appropriate indication for therapy in chronic hepatitis B infection, and other criteria in addition to ALT must be used to determine eligibility for therapy

Predictors of survival in chronic hepatitis B infection are surprisingly not well described. Various studies have identified different factors that were associated with adverse outcomes. For example, Niederau and colleagues,1 in a cohort of European patients, identified lack of clearance of hepatitis B e antigen (HBeAg) as a predictor of decreased survival. Others have identified older age, presence of cirrhosis, and the persistence of alanine aminotransferase (ALT) elevations as adverse prognostic signs in an antibody to hepatitis B e antigen (anti-HBe) positive cohort.2 In patients undergoing a flare of hepatitis B activity, whether spontaneous or chemotherapy induced, the presence of jaundice is an ominous sign.3 None of these adverse predictive factors are unexpected. Clearly, jaundice, cirrhosis, older age, and elevated ALT are obvious adverse predictive factors but until recently we have not had the tools to predict, years in advance, the outcome of chronic hepatitis B infection. This is important because we would prefer to offer treatment only to those who are likely to develop complications of the disease, and not to those whose disease will become inactive without long term sequelae. Recently, new predictors of outcome have been identified. At last year’s American Association for Study of Liver Disease (AASLD) meeting and the recent European Association for Study of the Liver (EASL) meeting, new data were presented that contribute to this debate. In addition, the article by Yuen and colleagues4 in this issue of Gut also forces us to re-examine some of our assumptions about hepatitis B prognosis and therefore treatment (see page 1610).

To some extent our current management algorithms have been directed by the pharmaceutical industry because management algorithms tended to follow the design of clinical trials used to license products. For example, the initial registration trials with lamivudine lasted one year.5 However, it has since become clear that for most patients one year of therapy with lamivudine (or any nucleoside analogue) provides inadequate seroconversion rates in HBeAg positive patients. It is also clear that most anti-HBe positive patients require extended, perhaps lifelong, therapy. Trials in HBeAg positive subjects chose HBeAg seroconversion as an end point because historically, seroconversion to anti-HBe positive was considered to be associated with inactivation of disease, with lower levels of viral replication and less inflammation.6 It now seems that e antigen seroconversion may be an inappropriate end point for many patients. At best interferon treatment only induces e antigen seroconversion in 30–35% of patients.7 The durability of this seroconversion is poor.8 The proportion of “sero-reverters” is even higher after seroconversion induced by one year of lamivudine therapy.9 Thus although randomised controlled studies have shown an increased seroconversion rate compared with controls in the short term, it is not clear that treatment induces more patients to undergo HBeAg seroconversion over the long term than would be expected without treatment.

Is it possible that treatment merely advances seroconversion by some uncertain period of time in those who are destined to seroconvert spontaneously at some future point? Perhaps therapy induced seroconversion merely advances spontaneous seroconversion by some years. An argument in favour of this hypothesis is that whether patients are treated with interferon or nucleoside analogues, those who have the highest likelihood of HBeAg seroconversion, namely those who have high ALT and low hepatitis B virus (HBV) DNA concentrations, are also those who have the highest likelihood of spontaneous seroconversion. Furthermore, Yuen and colleagues10 have observed matched cohorts of patients treated or not treated with interferon over an extended follow up period and have shown that beyond five years of follow up the proportion of treated patients who underwent seroconversion was the same as in the untreated group (that is, interferon therapy did not increase the overall number of patients undergoing seroconversion). It did however advance seroconversion by about five years. Nor did interferon therapy affect outcome. A study in children reached the same conclusion.11 Thus although in some populations treatment induced seroconversion appears to improve prognosis in the short term, it is not certain that treatment increases the overall number of patients undergoing e antigen seroconversions over the long term or improves the prognosis over the longer term.

Given the uncertainty about appropriate treatment end points, it is perhaps not surprising that the indications chosen for starting therapy have also been unsatisfactory. As the overall objective of treatment is to decrease inflammation, and hopefully thereby prevent all of the other complications of chronic hepatitis B, it seems logical to use an elevated ALT, a marker of hepatic inflammation, as an indication to start treatment. All of the registration trials have used this indication. All of the guidelines issued by various continental hepatology societies (AASLD, EASL, Asian Pacific Association for Study of the Liver (AASLD, EASL, Asian Pacific Association for Study of the Liver)12–15 supported the use of this indication. However, using elevated ALT as an indication for therapy means that only a small minority of all hepatitis B carriers will ever be treated, far fewer than the 20–25% of hepatitis B carriers who will die of complications of their liver disease. Using ALT as an indication for therapy will leave many patients who are destined to develop cirrhosis or hepatocellular carcinoma (HCC) untreated. The study by Yuen and colleagues4 in this issue of Gut, together with conclusions from a large scale prospective study in Taiwan,16 supports the conclusion that ALT alone is not an appropriate indication for therapy. In the Yuen study, patients who had an ALT concentration in the upper range of normal had an increased mortality from HCC compared with those in whom ALT levels were less than <0.5 × ULN. Paradoxically, the risk of HCC in patients with ALT levels that were higher than 2 × ULN was lower than in patients with lower ALT levels. Yuen et al explain this anomaly by assuming that higher levels of ALT represent flares similar to acute hepatitis, which resolve without leaving significant permanent injury. However, there may also be some selection bias influencing these results, in that patients with ALT >2 × ULN that persisted over time might have undergone therapy and been excluded from
this study. Others might have been in the process of seroconverting and going into remission. Yuen and colleagues also showed that the HBeAg status and ALT on follow up did not correlate with the incidence of complications. When they analysed HBV DNA they found, as did Chu and colleagues,14 that HBV DNA below 10^3 copies/ml did not protect against the development of complications.

The REVEAL study is one of three similar large scale, long term, prospective, cohort studies of hepatitis B carriers, all of which provide new evidence about identifying patients at risk of a poor outcome. The studies were performed in a cohort in Philadelphia,17 a cohort in Haimen City China,18 19 and in a cohort from several townships in Taiwan.15 20–22 Each cohort included more than 3000–4000 subjects who were recruited and followed for more than 10 years. The end points in all three were similar: incidence of HCC, cirrhosis, and death from liver disease. All three studies came to similar conclusions. The best predictor of an adverse outcome in a hepatitis B carrier was the HBV DNA concentration. The higher the HBV DNA the higher the incidence of an adverse outcome. Neither ALT22 nor e antigen status20 at recruitment was correlated with outcome. These results, together with the data of Yuen and colleagues,4 support the concept that patients with normal ALT levels can no longer be excluded from therapy, and that criteria other than the ALT must be used to determine eligibility for therapy.

How then can we distinguish between those hepatitis B carriers who need therapy and those who do not? Are there other markers of a poor prognosis that might be more useful? Liver biopsy showing fibrosis or cirrhosis may be one such marker but we cannot biopsy every hepatitis B carrier. Perhaps non-invasive measurements of fibrosis will help answer this question. However, if treatment is restricted to patients with advanced fibrosis the incidence of cancer might not fall a great deal. The only other logical marker is HBV DNA concentration. The three large cohort studies strongly suggest (but do not prove) that suppression of viral replication will decrease the incidence of adverse outcomes. There is other evidence to support this notion. Long term suppression of woodchuck hepatitis virus replication by entecavir leads to a reduction in the incidence of HCC.21 Suppression of viral replication in cirrhotic patients decreases the incidence of liver related adverse events (HCC and cirrhosis).24 (Whether suppression of HBV DNA before the onset of cirrhosis would have a similar effect is not known, and is unlikely to be studied, given the difficulty of maintaining a patient with active disease off therapy for an extended period of follow up.) Patients in whom viral replication is spontaneously suppressed early in the course of their disease are at a much lower risk of cirrhosis and HCC compared with those in whom viral replication persists.25 26 Finally, in the Taiwan cohort, patients in whom HBV DNA spontaneously improved had a lower incidence of adverse outcomes than those in whom HBV DNA levels remained high.27

This all suggests that a high HBV DNA concentration should be the prime indication for therapy. Several immediate questions arise. Firstly, at what point in the natural history is it appropriate to start treatment? This question cannot be answered at present and will have to await full publication of the cohort studies so that the relationship between HBV DNA, age at recruitment, and outcome can be evaluated. The next question is how low should the HBV DNA level be to have the highest likelihood of preventing complications of chronic HBV infection. In the three cohort studies, even HBV DNA concentrations <100 000 copies/ml were associated with a significant incidence of HCC, cirrhosis, and death from liver disease. Others have shown, in a small cohort, that all those with HCC had an HBV DNA concentration above 2x10^5.28 Until this level can be confirmed as “safe”, it is probably wise to aim to suppress HBV DNA maximally, to undetectable levels, or if that is not possible, to below 10^4 copies/ml.

Until recently we have not had adequate tools to achieve optimal suppression of viral replication indefinitely. Interferon based therapy only induces permanent suppression in a small proportion of patients.5 29 30 There are as yet no long term studies on the durability of pegylated interferon response, but at best, only 30–35% of HBeAg positive patients respond, leaving 65–70% requiring additional treatment.31 Lamivudine cannot be used long term because of the development of resistance.22 The prospect of using adefovir long term is also fading, as up to 18% resistance rates at four years have been reported.32 Entecavir is the most potent nucleoside analogue to complete phase III testing and, so far, no resistance has been reported in the treatment of naïve subjects.33 Tenofovir is more potent than adefovir34 but its HBV resistance profile and frequency of emergence of resistance remains unknown. However, it is inevitable that resistance will develop over time for both of these agents. There are as yet no data on the combined use of more than one nucleoside analogue, although this would seem to be a logical approach and perhaps the only approach that might provide long term viral suppression.

Given the above considerations, the time has come to abandon some of our old concepts about the management of hepatitis B. We should no longer rely on an elevated ALT to select patients for treatment. Patients with high viral loads and normal ALT levels are not good candidates for interferon and should probably only be treated with nucleos(t)-tide analogues. Treatment should aim to suppress viral replication as much as possible. The target should be undetectable HBV DNA and if that is not possible, HBV DNA should not exceed 10^4 copies/ml. The availability of more potent drugs such as entecavir, telbivudine, and clevudine will make these targets feasible. To ensure long term suppression we have to prevent the emergence of resistance. It may be that if viral replication is suppressed deeply enough, even with monotherapy, resistance will be rare, but addition of a second agent that does not have cross reactive resistance might be necessary. Cost will be a huge issue once we contemplate long term therapy, which will have to be confronted head-on. I believe that we will have to bite the bullet and immediately undertake studies of combination therapy, or risk creating strains of virus that are resistant to everything.

**SUMMARY**

- ALT is a poor predictor of outcome and therefore cannot be used as the sole indication for therapy.
- HBeAg positivity is associated with a higher risk of adverse outcomes than anti-HBe positivity.
- HBV DNA concentration at recruitment and during follow up is the best predictor of an adverse outcome.
- The higher the HBV DNA concentration (above 10^4 copies/ml), the greater the mortality.
- Treatment should be aimed at suppressing HBV DNA maximally, to below 10^4, and preferably to below 10^3.


Conflict of interest: declared (the declaration can be viewed on the Gut website at http://www.gutjnl.com/supplemental).

Correspondence to: Dr M Sherman, University of Toronto and University Health Network, Toronto General Hospital, 200 Elizabeth St, Toronto, Ontario M5G 2C4, Canada; morris.sherman@uhn.on.ca
Cirrhosis

Mortality from cirrhosis: lack of progress over the last 35 years

G Cluud

Liver cirrhosis mortality does not seem to have changed significantly during the last 30 years in the Oxford region! How come? There are risks of erroneous findings (patient mix consequences, wrong sampling unit, diagnostic misclassification, type II errors), lack of beneficial effects of interventions considered to be effective, and incorrect implementation of interventions

The findings of Roberts and colleagues¹ in this issue of Gut show a lack of improvement in liver cirrhosis mortality during the years 1968 to 1999 (see page 1615). This must be


Southern England. The analyses were based on discharge and death certificate statistics. One year after admittance, the mortality rate was 34%, and remained so during the entire 30 year observation period. One year after admittance, the standardised mortality rate was 16.3 times that of the general population. These findings were robust to different analytical strategies. The disappointing results during the 30 year period were obtained both for the total group of 8192 patient admissions as well as for the diagnostic subgroups individually. The data show how deadly liver cirrhosis has been and continues to be.

Why does cirrhosis mortality remain unaffected despite our diagnostic and treatment strategies? Does it is decreasing? We expect decreasing mortality due to the use of many new interventions. Interventions such as liver transplantation,¹ endoscopic treatment for bleeding varices,¹⁴ prevention of bleeding and rebleeding from varices with beta blockers,¹⁴ antiviral drugs for
hepatitis B or C,5,6 and antibiotics for preventing and treating complications to cirrhosis,3,7 have all been introduced during the study period.

Three major causes may explain the contrast between the finding of no significant change in mortality on the one hand and our expectation of decreasing mortality on the other: erroneous findings, misguided perceptions about the effectiveness of interventions, or incorrect implementation of interventions.

ERRONEOUS FINDINGS
A change in “patient mix” over time is a plausible possibility for erroneous findings. Nurses and physicians feel that the people they care for and treat are becoming more severely ill. The workload connected with the individual patient is rising, and so does the number of hospital admissions. Outpatient clinics are growing at a rate of approximately 2% per year. Part of this growth could be due to handling less diseased patients as outpatients. Accordingly, more severely diseased patients are admitted to hospital wards. This would raise mortality. But improved treatments keep the mortality at a constant level. Therefore, no net change in mortality is observed.

The patient mix could be influenced by diagnostic drift. Thirty years ago the diagnoses of “non-alcoholic steatohepatitis” and “non-alcoholic fibrosis and cirrhosis” were rarely used. These diagnoses have become trendy over the years.10 This may have moved the less severely diseased patients from the alcoholic cirrhosis group to the “new” diagnostic entities. Studies on the “new” non-alcoholic liver diagnoses rarely exclude alcohol problems by adequate means,11,12 so why should clinical reality be observed.

Roberts and colleagues1 have chosen the “wrong” sampling unit? During the past decades population based liver cirrhosis mortality rates have increased significantly in England, in contrast with other EU countries where it is falling.13 The increase in alcohol consumption may lead to increased mortality rates. This could impact on the patient mix and the findings. However, the findings of Roberts and colleagues1 concur with data from other regions of England14 and from Denmark.15

Roberts and colleagues1 used administrative discharge data for their identification of cases. Diagnostic discharge data are not entirely accurate and liver cirrhosis may have been misclassified in 5–10% of cases, according to the Danish experience.18 Such classification however would not explain the lack of improvement in liver cirrhosis mortality unless one could point to a systematic change connecting misclassification over time with changed mortality.

We must consider the possibility of a type II error—no improvement was detected although it actually happened. Nobody can exclude this possibility. The type II error is in fact substantial. Mortality during the period 1994 to 1999 had an odds ratio of 0.90 (95% confidence interval (CI) 0.74–1.09) compared with mortality in the period 1968–1973 (table 4 in Roberts and colleagues1). This corresponds to the finding that mortality may have decreased by 26% or increased by 9%. Only much larger studies, preferably including national or international data, may resolve this issue.

LACK OF BENEFICIAL EFFECT OF INTERVENTIONS CONSIDERED TO BE EFFECTIVE
The second major cause for the contrast between no significant improvement in mortality on the one hand and our expectation of improvements in mortality due to new methods for prevention, diagnosis, treatment, and care on the other is misguided expectations. Could it be that there has in reality been no improvement in mortality during the last 30 years?3

We have no randomised clinical trials demonstrating that cirrhosis mortality can be significantly decreased by liver transplantation. However, we have cohort studies and matched controlled and simulated studies suggesting that this may be so, but these analyses only point to the fact that Child class C patients may have a gain in survival.19 Furthermore, less than 25 Child class C patients undergo liver transplanted per year in the Oxford region. This number could not influence the statistics for a whole region.

Endoscopic banding in the primary prevention of variceal bleeding may prevent bleeding but endoscopic banding does not seem to have significant effects on mortality.20 Beta blockers are also recommended for primary prevention1 but we have been unable to demonstrate any significant effect of beta blockers on mortality in high quality trials (Chen W et al, unpublished observations).

Terlipressin and endoscopic interventions may significantly decrease mortality in patients with acute variceal bleeding. But we still lack information on the influence of these interventions on long term mortality.21,22

Prevention of rebleeding from varices with beta blockers, endoscopic measures, or transjugular intrahepatic portosystemic shunt (TIPS) may have significant effects on mortality but the results are modest.23–25 TIPS may remove more ascites but cause more hepatic encephalopathy and does not seem to have significant effects on mortality.20

Much marketing has gone into interventions for chronic hepatitis B and chronic hepatitis C. We do not have any firm knowledge on how interferons affect mortality in patients with chronic hepatitis B. Lamivudine seems to affect the clinical course in patients with chronic hepatitis B and advanced liver disease.20 However, we have no convincing evidence showing a significant effect of lamivudine20 on the mortality of chronic hepatitis B patients. The situation for patients with chronic hepatitis C is not much better. Combination therapy with interferon and ribavirin seems to be able to reduce the composite outcome measure of cirrhosis, hepatocellular carcinoma, and death.20 Combination therapy significantly reduced the composite outcome measure in all 9991 patients entered into 72 randomised clinical trials (relative risk 0.49 (95% CI 0.25–0.96; number needed to treat to benefit one patient 419 (95% CI 290–4523)) but not in naive, relapers, or non-responders individually.20 Furthermore, we found no significant effect of combination therapy on mortality as an isolated outcome.20

Antibiotics are recommended for preventing and treating complications of cirrhosis.3,8–10 Although antibiotics seem to reduce short term mortality we urgently need data on their influence on long term mortality.

INCORRECT IMPLEMENTATION
If the explanation that the interventions do not work is unpalatable, then try this: the interventions worked only a little in clinical research but were incorrectly applied in clinical practice.

We recently assessed the degree of concurrence between research evidence and clinical practice in Denmark.10,31 We evaluated the agreement between research evidence in Cochrane Hepato-Biliary Group systematic reviews32 and reported on the use of clinical interventions for typical patients presenting no contraindications. The Cochrane Hepato-Biliary Group had completed 28 systematic reviews on 36 interventions that were available in Denmark in 2002. Based on the reviews, three interventions with significant beneficial effects on clinical outcomes were classified as “evidence based” (n-acetylcysteine for paracetamol overdose,33 terlipressin for bleeding oesophageal varices,21 and antibiotics for patients with cirrhosis and gastrointestinal
bleeding) whereas 19 were classified as “possibly evidence based” and 14 as “not evidence based”. Questionnaires on reported use and perceived intervention effects were mailed to senior physicians practising in Danish hospitals and being responsible for the treatment of liver patients. The proportion of physicians who reported that they never used the three evidence based interventions varied considerably (2%, 57%, and 62%, respectively). The perceived intervention effect, duration of clinical experience, and employment in the headquarter of department, and university hospital employment were significant predictors of more frequent use of evidence based interventions. Physicians also reported that they used the interventions that were not evidence based more often if they were employed at a university hospital.

So we observed considerable disagreements between research evidence and reported clinical use in Denmark. Although I have no data to prove it, similar or other mechanisms in Oxford could explain incorrect implementation of interventions.

WHAT TO DO NOW?

As always, when things do not add up more than one thing may be wrong. Could it be a combination of erroneous findings, misguided expectations, and incorrect implementation? The findings in the study of Roberts and colleagues1 as well as the increased liver cirrhosis mortality rates in England over time—in contrast with other countries—call for further epidemiological studies in the UK and abroad. In addition to one year mortality, these studies should also examine five and 10 year mortality changes over time.

We may also need to adjust our expectations to the intervention effects. May be the interventions we use are not as effective as we imagine. We therefore urgently need to develop more effective interventions. In addition to finding new interventions for alcoholic liver cirrhosis, for example,14-17 we must develop preventive measures for the deadly consequences of the increasing alcohol problems in our societies. We also need to scrutinise the beneficial and harmful effects of the intervention we employ in daily clinical practice. In order to accomplish these developments we must become much better in collaborat- ing. Through collaboration we can direct much larger randomised clinical trials carried out with much better methodology.14-41

We also need more public support for clinical research and possibly less industry involvement.15 Finally, we need full transparency in clinical research with publication of and public access to all protocols, protocol amendments, and clinical data.44

Finally, all hospitals and departments should regularly check their clinical practices and clinical guidelines. We need collaboration on getting research into clinical practice. All departments need a team of systematic reviewers who are able to conduct high quality systematic reviews. Only by being able to do systematic reviews themselves will they become sufficiently critical of meta-analyses and the so-called “systematic reviews” carried out by others. Furthermore, such activities could benefit the systematic reviewers as well as their departments.46


doi: 10.1136/gut.2005.072876

Correspondence to: Dr C Gluud, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department of Biostatistics, Rigshospitalet, Copenhagen University Hospital, DK 2100 Copenhagen, Denmark; cgluud@ctu.dk

Conflict of interest: None declared.

REFERENCES


EDITOR’S QUIZ: GI SNAPSHOT

Answer

From question on page 1514

Histology confirmed this to be an enterolith adherent to the pouch. Our patient had a follow up evacuating pouchogram which showed stasis in the pouch. Food residue chronically accumulating would act as a nidus for enterolith formation. Morphological abnormalities of the pouch such as twist or mucosal bridge may have a role. We would recommend regular pouch washouts to prevent accumulation of residue and recurrent enterolith formation. Pouch patients may develop transient symptoms of frequency, incontinence, and leakage during pregnancy but these do settle after delivery. Persistent or new symptoms after delivery should be investigated. Plain x-rays, computed tomography scan, endoscopy, or examination under anaesthesia help to confirm the diagnosis. Removal of the enterolith can be attempted endoscopically or transanally. Laparotomy may become necessary and access into the pouch may be gained by incising the fundus. These patients require a period of follow up and an evacuating pouchogram to ensure return of good pouch function.

doi: 10.1136/gut.2004.062547